Amicus Therapeutics, Inc.

    Amicus Therapeutics, Inc.

    NNASDAQ:FOLD
    14.49
    USD
    0.00
    (0.00%)
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    0.01
    0.02
    - -
    0.04
    0.24
    0.49
    0.76
    1.01
    1.13
    1.14
    1.35
    1.74
    - -
    2.06
    Basic EPS, GAAP
    -1.16
    -0.93
    -1.2
    -1.49
    -1.85
    -1.88
    -1.48
    -1.07
    -0.92
    -0.82
    -0.51
    -0.18
    - -
    -0.09
    Free Cash Flow per Basic Share
    -0.91
    -0.7
    -0.95
    -1.16
    -1.42
    -1.61
    -1.04
    -0.9
    -0.75
    -0.58
    -0.23
    -0.11
    - -
    0.11
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -7.37
    -6
    -5.26
    -5.79
    -6.92
    -7.59
    -7.35
    -7.89
    -8.45
    -8.75
    -9.08
    -8.99
    - -
    -8.97
    Tangible Book Value per Share
    0.22
    1.18
    -3.06
    -2.41
    0.86
    0.66
    1.06
    0.25
    0.32
    -0.34
    -0.2
    -0.07
    - -
    0.2
    Basic Weighted Avg Shares
    51
    74
    110
    134
    153
    186
    240
    259
    271
    289
    295
    304
    - -
    308
    Sales/Revenue/Turnover
    - -
    1
    - -
    5
    37
    91
    182
    261
    306
    329
    399
    528
    634
    634
    Operating Margin (%)
    -17,133.06
    -5,609.8
    - -
    -3,530.88
    -571.03
    -356.71
    -165.03
    -93.47
    -65.44
    -62.09
    -18.4
    6.45
    5.44
    5.44
    Depreciation Expense
    2
    2
    2
    3
    4
    4
    5
    9
    6
    5
    8
    9
    7
    7
    Net Income, GAAP
    -60
    -69
    -132
    -200
    -284
    -349
    -356
    -277
    -250
    -237
    -152
    -56
    -27
    -27
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    14,293.72
    14,293.72
    Profit Margin (%)
    -16,427.82
    -5,631.21
    - -
    -4,034.73
    -769.03
    -382.48
    -195.56
    -106.12
    -81.98
    -71.85
    -37.96
    -10.62
    -4.27
    -4.27
    Working Capital
    78
    134
    143
    229
    322
    465
    391
    450
    451
    285
    315
    356
    438
    438
    LT Debt
    14
    11
    42
    154
    164
    322
    203
    435
    433
    444
    437
    435
    434
    434
    Total Equity
    46
    122
    348
    360
    353
    343
    476
    286
    307
    123
    160
    194
    274
    274
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -698.76
    -698.76
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    285.07
    285.07
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    ST Debt
    9
    9
    9
    LT Borrowings
    391
    392
    393
    LT Finance Leases
    43
    42
    41
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    308
    308
    311
    Market Capitalization
    1,758
    2,428
    4,388

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    Total Current Assets
    538
    594
    676
    Cash, Cash Equivalents & STI
    231
    264
    294
    Accounts Receivable, Net
    106
    114
    115
    Inventories
    155
    178
    229
    Total Current Liabilities
    168
    199
    238
    Payables & Accruals
    159
    190
    180
    ST Debt
    9
    9
    9
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    3.77%
    8%
    41.33%
    Free Cash Flow
    -23.56%
    -67.64%
    -197.8%
    Net Income, GAAP
    -6.96%
    -33.13%
    -51.68%
    Sales/Revenue/Turnover
    - -
    19.7%
    20.05%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    86
    95
    104
    115
    399
    2024
    110
    127
    142
    150
    528
    2025
    125
    155
    169
    185
    634

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.18
    -0.15
    -0.07
    - -
    -0.51
    2024
    -0.16
    -0.05
    -0.02
    - -
    -0.18
    2025
    -0.07
    -0.08
    0.06
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • nypost.com

      Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

    • seekingalpha.com

      BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

    • fool.com

      CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

    • seekingalpha.com

      BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy

    • defenseworld.net

      SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD

    • defenseworld.net

      Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD

    • businesswire.com

      Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications

    • defenseworld.net

      Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD

    • reuters.com

      Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD

    • zacks.com

      Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues

    • defenseworld.net

      Amicus Therapeutics, Inc. $FOLD Shares Sold by Granite Investment Partners LLC

    • gurufocus.com

      Market Today: Blue Owl payout, GDP miss, oil and EV moves

    • globenewswire.com

      Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

    • zacks.com

      What to Expect From These Drug/Biotech Players This Earnings Season?

    • zacks.com

      Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?

    • globenewswire.com

      Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

    • zacks.com

      FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?

    • defenseworld.net

      Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

    • businesswire.com

      FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

    • 247wallst.com

      Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More